The efficacy of olaparib as salvage therapy in an advanced intrahepatic cholangiocarcinoma patient harboring somatic BRCA1 and PALB2 pathogenic variants: a case report and literature review
BackgroundFor advanced biliary tract cancer (BTC) patients with BRCA pathogenic variants who have failed first-line treatment, the optimal treatment strategy remains to be established. Olaparib, the first FDA-approved poly adenosine diphosphate-ribose polymerase inhibitors (PARPi), is commonly utili...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2025.1558677/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|